- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT03098654
Impact of Integrated HIV/NCD Screening on HIV Testing Uptake and Engagement in HIV Care In Kisarawe, Tanzania
Impact of Integrated HIV/NCD Screening on HIV Testing Uptake and Engagement in HIV Care: An RCT In Kisarawe, Tanzania
This study focuses on the integration of HIV and NCD screening and care. The investigators will conduct a randomized controlled trial examining the efficacy and cost-effectiveness of the intervention strategy in Kisarawe District, Tanzania, a rural area 40 KM southwest of Dar es Salaam. The study will match two similar HIV care and treatment centers (CTC) in the District, one of which will be randomized to receive the enhanced intervention which will integrate diabetes (DM) and hypertension (HTN) screening with the existing HIV testing program, and integrate care for DM and HTN into the HIV care program. Comparisons of the community HIV testing rates in the two communities, engagement in HIV care among those testing positive, and 24-month retention in HIV care will be assessed among a cohort of 107 newly enrolled patients per community.
Specifically, the aims are to determine:
- Whether integrating DM and HTN screening with HIV testing will increase the uptake of community-level HIV testing.
- If integrating DM/HTN care with HIV care enhances engagement in HIV care.
- Whether integration of DM/HTN care with HIV care enhances retention in HIV care for those newly enrolled in HIV care.
- The cost-effectiveness of integrating NCD screening and care with HIV screening and care with regard to the incremental cost per HIV infected client engaged in HIV care, and cost per newly enrolled HIV client retained in HIV care over 24-months.
Tutkimuksen yleiskatsaus
Tila
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Dar Es Salaam, Tansania
- Muhimbili University of Health and Allied Sciences
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Eligibility Criteria for Screening:
• Be aged 18 years or above.
Inclusion Criteria for Intervention and Control Cohorts:
- Be aged 18 years or above.
- Recently enrolled in HIV care and treatment
Exclusion Criteria:
- Potentially vulnerable populations (incarcerated, under age of consent, unable to understand the procedures planned, etc.).
- Individuals under the influence of drugs or alcohol and anyone presenting with mental disability that would preclude ability to understand study procedure, risks, and benefits.
- Inability or unwillingness of subject to provide informed consent.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Enhanced Intervention
Members will have DM and HTN managed at the CTC together with their HIV care. Interventions include:
|
Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor.
Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken.
Blood pressure will be assessed using a portable battery operated automatic BP cuff.
The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
Muut nimet:
All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed.
Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
Muut nimet:
|
Ei väliintuloa: Control
Members in the control arm will receive community-level rapid HIV testing at the CTCs, which is the standard of care.
HIV testing performed by the CTC is according to the National HIV Testing Algorithm (serial rapid testing using Determine HIV 1/2 and Uni-Gold HIV 1/2) which follows Tanzanian and international (WHO/CDC) standards for provision of HIV counseling and testing.
Those who test positive for HIV will be referred to the CTC for the standard Tanzanian level of HIV care, which includes counseling and ART medication managed at the CTCs.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Uptake of community-level HIV testing
Aikaikkuna: 12 months
|
Uptake of HIV testing will be measured as the annual cumulative number of unique persons receiving HIV testing as a proportion of the community size in each HIV CTC venue using clinic records from the government CTC.
|
12 months
|
Engagement in HIV care
Aikaikkuna: 12 months
|
Engagement will be measured as proportion of persons testing positive for HIV who advance to successful enrollment in HIV care at the CTC.
Persons will be documented with biometric fingerprint matching against those who tested for HIV in the study area.
Comparisons will be made across the enhanced and comparison CTCs.
|
12 months
|
Retention in HIV care
Aikaikkuna: 24 months
|
Retention in HIV care will be measured in several ways, including the Human Resources and Services Administration HIV/AIDS Bureau definition of 2 or more outpatient visits at least 3-months apart during each year, the number of missed clinic visits, and appointment adherence (number of completed visits/number of scheduled visits) during the study period.
|
24 months
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Adherence to DM/HTN/ARV medication
Aikaikkuna: 24 months
|
Self-reported medication adherence questions adapted from our other NIH-funded study (Dyadic-Based Diagnosis, Care, and Prevention for HIV Discordant Couples) will be used to assess medication adherence.
The Self-Reported Medication Nonadherence Measurement tool will be used to assess reasons for nonadherence.
|
24 months
|
Adherence to physical activity intervention
Aikaikkuna: 24 months
|
Global Physical Activity Questionnaire (GPAQ) to assess DM / HTN lifestyle changes for NCD positive subjects in the intervention arm.
The GPAQ is a 12-item survey created by the World Health Organization to measure physical activity (intensity, duration, and frequency) and domains of performance (related to occupation, transportation, and leisure).
|
24 months
|
Adherence to dietary intervention
Aikaikkuna: 24 months
|
A food frequency questionnaire developed for use specifically in Tanzania and surrounding countries will be used to assess dietary changes.
|
24 months
|
Biological, Psychological, and Social adverse events associated with the study intervention
Aikaikkuna: 24 months
|
Self-reported and staff-reported adverse events (biological, psychological, or social) experienced as an outcome of receiving the intervention.
|
24 months
|
Cost-effectiveness of integrating NCD screening and care with HIV screening and care
Aikaikkuna: 24 months
|
Cost will be measured through regular cost worksheets that the investigators will collect throughout the duration of the study.
|
24 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Yhteistyökumppanit
Tutkijat
- Päätutkija: Michael D. Sweat, PhD, Medical University of South Carolina
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Glukoosiaineenvaihduntahäiriöt
- Metaboliset sairaudet
- RNA-virusinfektiot
- Virussairaudet
- Infektiot
- Veren välityksellä leviävät infektiot
- Tartuntataudit
- Sukupuolitaudit, virus
- Sukupuolitaudit
- Lentivirus-infektiot
- Retroviridae-infektiot
- Immuunijärjestelmän sairaudet
- Endokriinisen järjestelmän sairaudet
- Diabetes mellitus
- Hitaat virustaudit
- HIV-infektiot
- Diabetes mellitus, tyyppi 2
- Immuunikato
- Immunologiset puutosoireyhtymät
- Hypoglykeemiset aineet
- Huumeiden fysiologiset vaikutukset
- Metformiini
Muut tutkimustunnusnumerot
- Pro00064733
- 1R01MH111366-01 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Hypertensio
-
National Taiwan University Hospital Hsin-Chu BranchRekrytointiHypertensio, välttämätön | Hypertensio, NaamioituTaiwan
-
University of Alabama at BirminghamTroy UniversityValmisHypertensio | Hypertensio, kestää perinteistä hoitoa | Hallitsematon hypertensio | Hypertensio, valkoinen takkiYhdysvallat
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Aktiivinen, ei rekrytointiValkoisen turkin hypertensio | Hypertensio, välttämätönYhdysvallat
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesValmisHypertensio, kestää perinteistä hoitoa | Primaarinen hypertensioKiina
-
University Hospital of CologneTuntematonNAFLD; Hypertensio, White-coat-hypertensio, naamioitunut hypertensioSaksa
-
Cytos Biotechnology AGValmisLievä essentiaalinen hypertensio | Kohtalainen essentiaalinen hypertensioSveitsi
-
Inonu UniversityEi vielä rekrytointiaHypertensio, Essential Hypertensio
-
Istituto Auxologico ItalianoRekrytointiHypertensio, välttämätön | Hypertensio, hallitsematonArgentiina, Kiina
-
BayerValmis
-
BackBeat Medical IncRekrytointiHypertensio, välttämätön | Systolinen hypertensioPuola, Tšekki, Unkari